{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:05:00Z","timestamp":1786460700546,"version":"build-2736575974"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Colorectal cancer (CRC) remains a major global health challenge, ranking as the third most common malignancy and the second leading cause of cancer-related mortality worldwide. This study aimed to evaluate a novel series of pyrazolo[4,3-\n                    <jats:italic>e<\/jats:italic>\n                    ][1,2,4]triazine and pyrazolo[4,3-\n                    <jats:italic>e<\/jats:italic>\n                    ]tetrazolo[1,5-\n                    <jats:italic>b<\/jats:italic>\n                    ][1,2,4]triazine sulfonamides as potential anticancer agents, with a focus on their cytotoxic and mechanistic effects against CRC cell lines. Incorporation of the tetrazole ring significantly increased cytotoxic activity (up to 50-fold) and selectivity (3.6-9.2-fold) compared to non-tetrazole analogues (2.2\u20133.3). Pyrazolo-tetrazolo-triazine derivatives exhibited IC\u2085\u2080 values ranging from 0.12 to 1.1 \u00b5M and demonstrated enhanced solubility and consistent biological activity. Selected derivatives (MM134, MM136, MM137, MM139) induced marked DNA damage and inhibition of cell proliferation, with cell cycle analysis confirming apoptotic and necrotic features depending on the compound and exposure time. Electrochemical analyses confirmed direct interactions between MM compounds and double-stranded DNA. Notably, MM137 was the potent inducer of cell death in both HCT-116 and HT-29 3D spheroids at concentrations as low as 5 \u00b5M, comparable to the most pre-clinically advanced MM129 derivative. In conclusion, the study highlights pyrazolo[4,3-\n                    <jats:italic>e<\/jats:italic>\n                    ]tetrazolo[1,5-\n                    <jats:italic>b<\/jats:italic>\n                    ][1,2,4]triazine sulfonamides as promising anticancer candidates with potent cytotoxicity, favorable selectivity, and potential multimodal mechanisms of action.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-52451-5","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:44:34Z","timestamp":1780299874000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting colorectal cancer with pyrazolo[4,3-e][1,2,4]triazine and pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine sulfonamides: comprehensive in vitro evaluation"],"prefix":"10.1038","volume":"16","author":[{"given":"Mateusz","family":"Kciuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Machura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Wanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylwia","family":"Smarzewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Mojzych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"P\u0142uciennik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Kontek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,31]]},"reference":[{"key":"52451_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16081530","volume":"16","author":"G Roshandel","year":"2024","unstructured":"Roshandel, G., Ghasemi-Kebria, F. & Malekzadeh, R. Colorectal cancer: Epidemiology, risk factors, and prevention. Cancers 16, 1530 (2024).","journal-title":"Cancers"},{"key":"52451_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18010197","volume":"18","author":"I M\u00e1rmol","year":"2017","unstructured":"M\u00e1rmol, I., S\u00e1nchez-de-Diego, C., Pradilla Dieste, A., Cerrada, E. & Rodriguez Yoldi, M. J. Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. Int. J. Mol. Sci. 18, 197 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"52451_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/10732748211056692","volume":"29","author":"A Lewandowska","year":"2022","unstructured":"Lewandowska, A., Rudzki, G., Lewandowski, T., Stryjkowska-G\u00f3ra, A. & Rudzki, S. Risk factors for the diagnosis of colorectal cancer. Cancer Control 29, 10732748211056692 (2022).","journal-title":"Cancer Control"},{"key":"52451_CR4","first-page":"195","volume":"15","author":"V Aran","year":"2016","unstructured":"Aran, V., Victorino, A. P., Thuler, L. C. & Ferreira, C. G. Colorectal cancer: Epidemiology, disease mechanisms and interventions to reduce onset and mortality. Clin. Colorectal Cancer 15, 195\u2013203 (2016).","journal-title":"Clin. Colorectal Cancer"},{"key":"52451_CR5","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2147\/CIA.S109285","volume":"11","author":"K Simon","year":"2016","unstructured":"Simon, K. Colorectal cancer development and advances in screening. Clin. Interv. Aging 11, 967\u2013976 (2016).","journal-title":"Clin. Interv. Aging"},{"key":"52451_CR6","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.2174\/0929867324666170111152436","volume":"24","author":"RM McQuade","year":"2017","unstructured":"McQuade, R. M., Stojanovska, V., Bornstein, J. C. & Nurgali, K. Colorectal cancer chemotherapy: The evolution of treatment and new approaches. Curr. Med. Chem. 24, 1537\u20131557 (2017).","journal-title":"Curr. Med. Chem."},{"key":"52451_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000091441","volume":"22","author":"S Goyle","year":"2005","unstructured":"Goyle, S. & Maraveyas, A. Chemotherapy for colorectal cancer. Dig. Surg. 22, 401\u2013414 (2005).","journal-title":"Dig. Surg."},{"key":"52451_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/00001622-200107000-00011","volume":"13","author":"A Grothey","year":"2001","unstructured":"Grothey, A. & Schmoll, H. J. New chemotherapy approaches in colorectal cancer. Curr. Opin. Oncol. 13, 275\u2013286 (2001).","journal-title":"Curr. Opin. Oncol."},{"key":"52451_CR9","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.21037\/jgo.2019.06.03","volume":"10","author":"GHJ Chan","year":"2019","unstructured":"Chan, G. H. J. & Chee, C. E. Making sense of adjuvant chemotherapy in colorectal cancer. J. Gastrointest. Oncol. 10, 1183\u20131192 (2019).","journal-title":"J. Gastrointest. Oncol."},{"key":"52451_CR10","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.2174\/1871520622666220404082648","volume":"22","author":"N Kumar","year":"2022","unstructured":"Kumar, N. & Goel, N. Heterocyclic compounds: Importance in anticancer drug discovery. Anticancer Agents Med. Chem. 22, 3196\u20133207 (2022).","journal-title":"Anticancer Agents Med. Chem."},{"key":"52451_CR11","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.2174\/0929867323666160809093930","volume":"23","author":"D Kumar","year":"2016","unstructured":"Kumar, D. & Jain, S. K. A comprehensive review of N-heterocycles as cytotoxic agents. Curr. Med. Chem. 23, 4338\u20134394 (2016).","journal-title":"Curr. Med. Chem."},{"key":"52451_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25173948","author":"Z Bernat","year":"2020","unstructured":"Bernat, Z., Szymanowska, A., Kciuk, M., Kotwica-Mojzych, K. & Mojzych, M. Review of the synthesis and anticancer properties of Pyrazolo[4,3-e][1,2,4]triazine derivatives. Molecules https:\/\/doi.org\/10.3390\/molecules25173948 (2020).","journal-title":"Molecules"},{"key":"52451_CR13","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.2174\/0929867033456585","volume":"10","author":"G Bouchain","year":"2003","unstructured":"Bouchain, G. & Delorme, D. Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: Synthesis and antiproliferative evaluation. Curr. Med. Chem. 10, 2359\u20132372 (2003).","journal-title":"Curr. Med. Chem."},{"key":"52451_CR14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.2174\/092986708783497300","volume":"15","author":"XC Cheng","year":"2008","unstructured":"Cheng, X. C., Wang, Q., Fang, H. & Xu, W. F. Role of sulfonamide group in matrix metalloproteinase inhibitors. Curr. Med. Chem. 15, 368\u2013373 (2008).","journal-title":"Curr. Med. Chem."},{"key":"52451_CR15","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1007\/s11095-012-0828-z","volume":"29","author":"Y Lu","year":"2012","unstructured":"Lu, Y., Chen, J., Xiao, M., Li, W. & Miller, D. D. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm. Res. 29, 2943\u20132971 (2012).","journal-title":"Pharm. Res."},{"key":"52451_CR16","doi-asserted-by":"publisher","first-page":"6616","DOI":"10.1016\/j.bmc.2014.10.009","volume":"22","author":"M Mojzych","year":"2014","unstructured":"Mojzych, M., Dolashki, A. & Voelter, W. Synthesis of pyrazolo[4,3-e][1,2,4]triazine sulfonamides, novel Sildenafil analogs with tyrosinase inhibitory activity. Bioorg. Med. Chem. 22, 6616\u20136624 (2014).","journal-title":"Bioorg. Med. Chem."},{"key":"52451_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/14756366.2016.1238362","volume":"32","author":"M Mojzych","year":"2017","unstructured":"Mojzych, M. et al. Synthesis of chiral pyrazolo[4,3-e][1,2,4]triazine sulfonamides with tyrosinase and urease inhibitory activity. J. Enzyme Inhib. Med. Chem. 32, 99\u2013105 (2017).","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"52451_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113837","volume":"226","author":"Y Wan","year":"2021","unstructured":"Wan, Y., Fang, G., Chen, H., Deng, X. & Tang, Z. Sulfonamide derivatives as potential anti-cancer agents and their SARs elucidation. Eur. J. Med. Chem. 226, 113837 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"52451_CR19","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.3390\/cancers13133203","volume":"13","author":"JM Hermanowicz","year":"2021","unstructured":"Hermanowicz, J. M. et al. MM-129 as a novel inhibitor targeting PI3K\/AKT\/mTOR and PD-L1 in colorectal cancer. Cancers 13, 3203 (2021).","journal-title":"Cancers"},{"key":"52451_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310959","volume":"24","author":"M Kciuk","year":"2023","unstructured":"Kciuk, M. et al. Pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine sulfonamides as an important scaffold for anticancer drug discovery-in vitro and in silico evaluation. Int. J. Mol. Sci. 24, 10959 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"52451_CR21","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.3390\/pharmaceutics13081222","volume":"13","author":"JM Hermanowicz","year":"2021","unstructured":"Hermanowicz, J. M. et al. Preclinical toxicity and safety of MM-129-first-in-class BTK\/PD-L1 inhibitor as a potential candidate against colon cancer. Pharmaceutics 13, 1222 (2021).","journal-title":"Pharmaceutics"},{"key":"52451_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ejmech.2014.03.054","volume":"78","author":"M Mojzych","year":"2014","unstructured":"Mojzych, M. et al. Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines. Eur. J. Med. Chem. 78, 217\u2013224 (2014).","journal-title":"Eur. J. Med. Chem."},{"key":"52451_CR23","doi-asserted-by":"publisher","first-page":"5221","DOI":"10.3390\/ijms21155221","volume":"21","author":"A Gornowicz","year":"2020","unstructured":"Gornowicz, A., Szymanowska, A., Mojzych, M., Bielawski, K. & Bielawska, A. The effect of novel 7-methyl-5-phenyl-pyrazolo[4,3-e]tetrazolo[4,5-b][1,2,4]triazine sulfonamide derivatives on apoptosis and autophagy in DLD-1 and HT-29 colon cancer cells. Int. J. Mol. Sci. 21, 5221 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"52451_CR24","doi-asserted-by":"publisher","unstructured":"Mojzych, M. & Rykowski, A. Synthesis of functionalized 1H-Pyrazolo[4,3-e][1,2,4]triazines and their fused derivatives via Ipso-substitution of methylsulfonyl group with O-, N-, S- and C-Nucleophiles. Cheminform 35\u00a0(2004). https:\/\/doi.org\/10.1002\/chin.200450133.","DOI":"10.1002\/chin.200450133"},{"key":"52451_CR25","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1016\/j.bmc.2015.04.011","volume":"23","author":"M Mojzych","year":"2015","unstructured":"Mojzych, M. et al. New pyrazolo[4,3-e][1,2,4]triazine sulfonamides as carbonic anhydrase inhibitors. Bioorg. Med. Chem. 23, 3674\u20133680 (2015).","journal-title":"Bioorg. Med. Chem."},{"key":"52451_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2025.2594158","volume":"40","author":"OK Szewczyk-Roszczenko","year":"2025","unstructured":"Szewczyk-Roszczenko, O. K. et al. Sulphonamide derivatives with a triazine core as novel inducers of apoptosis and pyroptosis in glioblastoma multiforme cells. J. Enzyme Inhib. Med. Chem. 40, 2594158 (2025).","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"52451_CR27","doi-asserted-by":"publisher","unstructured":"Kciuk, M. et al. Preparation of novel pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine sulfonamides and their experimental and computational biological studies. Int J. Mol. Sci. 23(11):5892\u00a0(2022). https:\/\/doi.org\/10.3390\/ijms23115892.","DOI":"10.3390\/ijms23115892"},{"key":"52451_CR28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/14756366.2021.1879803","volume":"36","author":"JM Hermanowicz","year":"2021","unstructured":"Hermanowicz, J. M. et al. Exploration of novel heterofused 1,2,4-triazine derivative in colorectal cancer. J. Enzyme Inhib. Med. Chem. 36, 535\u2013548 (2021).","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"52451_CR29","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.molcel.2015.12.004","volume":"61","author":"J Zimmer","year":"2016","unstructured":"Zimmer, J. et al. Targeting BRCA1 and BRCA2 deficiencies with G-quadruplex-interacting compounds. Mol. Cell. 61, 449\u2013460 (2016).","journal-title":"Mol. Cell."},{"key":"52451_CR30","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1248\/bpb.25.1600","volume":"25","author":"G Da Violante","year":"2002","unstructured":"Da Violante, G. et al. Evaluation of the cytotoxicity effect of dimethyl sulfoxide (DMSO) on Caco2\/TC7 colon tumor cell cultures. Biol. Pharm. Bull. 25, 1600\u20131603 (2002).","journal-title":"Biol. Pharm. Bull."},{"key":"52451_CR31","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/0014-4827(88)90265-0","volume":"175","author":"NP Singh","year":"1988","unstructured":"Singh, N. P., McCoy, M. T., Tice, R. R. & Schneider, E. L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell. Res. 175, 184\u2013191 (1988).","journal-title":"Exp. Cell. Res."},{"key":"52451_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/toxres\/tfaa093","volume":"10","author":"E Cordelli","year":"2021","unstructured":"Cordelli, E., Bignami, M. & Pacchierotti, F. Comet assay: a versatile but complex tool in genotoxicity testing. Toxicol. Res. 10, 68\u201378 (2021).","journal-title":"Toxicol. Res."},{"key":"52451_CR33","doi-asserted-by":"publisher","first-page":"111865","DOI":"10.1016\/j.fct.2020.111865","volume":"147","author":"D Muruzabal","year":"2021","unstructured":"Muruzabal, D., Collins, A. & Azqueta, A. The enzyme-modified comet assay: Past, present and future. Food Chem. Toxicol. Int. J. Publ Br. Ind. Biol. Res. Assoc. 147, 111865 (2021).","journal-title":"Food Chem. Toxicol. Int. J. Publ Br. Ind. Biol. Res. Assoc."},{"key":"52451_CR34","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.trecan.2020.10.006","volume":"7","author":"NA Owiti","year":"2021","unstructured":"Owiti, N. A., Nagel, Z. D. & Engelward, B. P. Fluorescence sheds light on DNA damage, DNA repair, and mutations. Trends Cancer 7, 240\u2013248 (2021).","journal-title":"Trends Cancer"},{"key":"52451_CR35","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1038\/s41596-020-0398-1","volume":"15","author":"P M\u00f8ller","year":"2020","unstructured":"M\u00f8ller, P. et al. Minimum Information for Reporting on the Comet Assay (MIRCA): recommendations for describing comet assay procedures and results. Nat. Protoc. 15, 3817\u20133826 (2020).","journal-title":"Nat. Protoc."},{"key":"52451_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24044053","volume":"24","author":"M Kciuk","year":"2023","unstructured":"Kciuk, M. et al. Genotoxicity of novel Pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine Sulfonamides in normal and cancer cells in vitro. Int. J. Mol. Sci. 24, 4053 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"52451_CR37","doi-asserted-by":"publisher","unstructured":"Bukowski, K., Marciniak, B., Kciuk, M., Mojzych, M. & Kontek, R. Pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine sulfonamides as novel potential anticancer agents: Cytotoxic and genotoxic activities in vitro. Molecules. 27(12):3761 (2022). https:\/\/doi.org\/10.3390\/molecules27123761.","DOI":"10.3390\/molecules27123761"},{"key":"52451_CR38","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/978-1-4939-7831-1_24","volume":"1782","author":"S Deshwal","year":"2018","unstructured":"Deshwal, S., Antonucci, S., Kaludercic, N. & Di Lisa, F. Measurement of Mitochondrial ROS Formation. Methods Mol. Biol. Clifton NJ. 1782, 403\u2013418 (2018).","journal-title":"Methods Mol. Biol. Clifton NJ"},{"key":"52451_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.678343","volume":"11","author":"C Sargiacomo","year":"2021","unstructured":"Sargiacomo, C., Stonehouse, S., Moftakhar, Z., Sotgia, F. & Lisanti, M. P. MitoTracker Deep Red (MTDR) is a metabolic inhibitor for targeting mitochondria and eradicating cancer stem cells (CSCs), with anti-tumor and anti-metastatic activity in vivo. Front. Oncol. 11, 678343 (2021).","journal-title":"Front. Oncol."},{"key":"52451_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2016.00076","volume":"10","author":"B Xiao","year":"2016","unstructured":"Xiao, B., Deng, X., Zhou, W. & Tan, E.-K. Flow cytometry-based assessment of mitophagy using MitoTracker. Front. Cell. Neurosci. 10, 76 (2016).","journal-title":"Front. Cell. Neurosci."},{"key":"52451_CR41","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/nprot.2006.238","volume":"1","author":"C Riccardi","year":"2006","unstructured":"Riccardi, C. & Nicoletti, I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat. Protoc. 1, 1458\u20131461 (2006).","journal-title":"Nat. Protoc."},{"key":"52451_CR42","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.redox.2013.12.020","volume":"2","author":"BM Gyori","year":"2014","unstructured":"Gyori, B. M., Venkatachalam, G., Thiagarajan, P. S., Hsu, D. & Clement, M.-V. OpenComet: An automated tool for comet assay image analysis. Redox Biol. 2, 457\u2013465 (2014).","journal-title":"Redox Biol."},{"key":"52451_CR43","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.prot4493","volume":"2006","author":"S Kasibhatla","year":"2006","unstructured":"Kasibhatla, S. et al. Acridine Orange\/Ethidium Bromide (AO\/EB) staining to detect apoptosis. Cold Spring Harb. Protoc. 2006, pdb.prot4493 (2006).","journal-title":"Cold Spring Harb. Protoc."},{"key":"52451_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.12659\/MSMBR.893327","volume":"21","author":"K Liu","year":"2015","unstructured":"Liu, K., Liu, P., Liu, R. & Wu, X. Dual AO\/EB staining to detect apoptosis in osteosarcoma cells compared with flow cytometry. Med. Sci. Monit. Basic Res. 21, 15\u201320 (2015).","journal-title":"Med. Sci. Monit. Basic Res."},{"key":"52451_CR45","first-page":"1","volume":"1","author":"C Lema","year":"2011","unstructured":"Lema, C., Varela-Ramirez, A. & Aguilera, R. J. Differential nuclear staining assay for high-throughput screening to identify cytotoxic compounds. Curr. Cell. Biochem. 1, 1\u201314 (2011).","journal-title":"Curr. Cell. Biochem."},{"key":"52451_CR46","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.prot087288","author":"LC Crowley","year":"2016","unstructured":"Crowley, L. C., Marfell, B. J., Scott, A. P. & Waterhouse, N. J. Quantitation of apoptosis and necrosis by Annexin V binding, Propidium Iodide uptake, and flow cytometry. Cold Spring Harb. Protoc. https:\/\/doi.org\/10.1101\/pdb.prot087288 (2016).","journal-title":"Cold Spring Harb. Protoc."},{"key":"52451_CR47","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1023\/A:1022945107762","volume":"8","author":"JD Ly","year":"2003","unstructured":"Ly, J. D., Grubb, D. R. & Lawen, A. The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update. Apoptosis Int. J. Program. Cell. Death. 8, 115\u2013128 (2003).","journal-title":"Apoptosis Int. J. Program. Cell. Death"},{"key":"52451_CR48","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/002215540104901010","volume":"49","author":"DV Krysko","year":"2001","unstructured":"Krysko, D. V., Roels, F., Leybaert, L. & D\u2019Herde, K. Mitochondrial transmembrane potential changes support the concept of mitochondrial heterogeneity during apoptosis. J. Histochem. Cytochem. Off J. Histochem. Soc. 49, 1277\u20131284 (2001).","journal-title":"J. Histochem. Cytochem. Off J. Histochem. Soc."},{"key":"52451_CR49","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.prot087247","author":"LC Crowley","year":"2016","unstructured":"Crowley, L. C., Chojnowski, G. & Waterhouse, N. J. Measuring the DNA content of cells in apoptosis and at different cell-cycle stages by Propidium Iodide staining and flow cytometry. Cold Spring Harb. Protoc. https:\/\/doi.org\/10.1101\/pdb.prot087247 (2016).","journal-title":"Cold Spring Harb. Protoc."},{"key":"52451_CR50","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1080\/00032719.2014.1003425","volume":"49","author":"J Zavazalova","year":"2016","unstructured":"Zavazalova, J., Prochazkova, K. & Schwarzova-Peckova, K. Boron-doped diamond electrodes for voltammetric determination of Benzophenone-3. Anal. Lett. 49, 80\u201391 (2016).","journal-title":"Anal. Lett."},{"key":"52451_CR51","first-page":"89","volume":"14","author":"P Rawla","year":"2019","unstructured":"Rawla, P., Sunkara, T. & Barsouk, A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Przeglad Gastroenterol. 14, 89\u2013103 (2019).","journal-title":"Przeglad Gastroenterol."},{"key":"52451_CR52","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.3390\/cancers14071732","volume":"14","author":"MS Hossain","year":"2022","unstructured":"Hossain, M. S. et al. Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies. Cancers 14, 1732 (2022).","journal-title":"Cancers"},{"key":"52451_CR53","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/1758834015614530","volume":"8","author":"WA Hammond","year":"2016","unstructured":"Hammond, W. A., Swaika, A. & Mody, K. Pharmacologic resistance in colorectal cancer: a review. Ther. Adv. Med. Oncol. 8, 57\u201384 (2016).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"52451_CR54","doi-asserted-by":"publisher","first-page":"495","DOI":"10.4240\/wjgs.v15.i4.495","volume":"15","author":"A Kumar","year":"2023","unstructured":"Kumar, A. et al. Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review. World J. Gastrointest. Surg. 15, 495\u2013519 (2023).","journal-title":"World J. Gastrointest. Surg."},{"key":"52451_CR55","doi-asserted-by":"publisher","first-page":"1208140","DOI":"10.3389\/fonc.2023.1208140","volume":"13","author":"S Tirendi","year":"2023","unstructured":"Tirendi, S. et al. Colorectal cancer and therapy response: a focus on the main mechanisms involved. Front. Oncol. 13, 1208140 (2023).","journal-title":"Front. Oncol."},{"key":"52451_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27248708","volume":"27","author":"MJ Alam","year":"2022","unstructured":"Alam, M. J. et al. Recent advancement in drug design and discovery of pyrazole biomolecules as cancer and inflammation therapeutics. Molecules 27, 8708 (2022).","journal-title":"Molecules"},{"key":"52451_CR57","doi-asserted-by":"publisher","first-page":"12724","DOI":"10.3390\/ijms241612724","volume":"24","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. Recent advances in the development of pyrazole derivatives as anticancer agents. Int. J. Mol. Sci. 24, 12724 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"52451_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115599","volume":"28","author":"N Dhiman","year":"2020","unstructured":"Dhiman, N., Kaur, K. & Jaitak, V. Tetrazoles as anticancer agents: A review on synthetic strategies, mechanism of action and SAR studies. Bioorg. Med. Chem. 28, 115599 (2020).","journal-title":"Bioorg. Med. Chem."},{"key":"52451_CR59","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/cbdd.14103","volume":"100","author":"A Verma","year":"2022","unstructured":"Verma, A. et al. Tetrazole: A privileged scaffold for the discovery of anticancer agents. Chem. Biol. Drug Des. 100, 419\u2013442 (2022).","journal-title":"Chem. Biol. Drug Des."},{"key":"52451_CR60","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.2174\/1871520617666170327143148","volume":"17","author":"EA Popova","year":"2018","unstructured":"Popova, E. A., Protas, A. V. & Trifonov, R. E. Tetrazole derivatives as promising anticancer agents. Anticancer Agents Med. Chem. 17, 1856\u20131868 (2018).","journal-title":"Anticancer Agents Med. Chem."},{"key":"52451_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28114278","volume":"28","author":"Q Dai","year":"2023","unstructured":"Dai, Q. et al. Antitumor activity of s-triazine derivatives: A systematic review. Molecules 28, 4278 (2023).","journal-title":"Molecules"},{"key":"52451_CR62","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ejmech.2017.09.035","volume":"142","author":"S Cascioferro","year":"2017","unstructured":"Cascioferro, S. et al. 1,3,5-Triazines: A promising scaffold for anticancer drugs development. Eur. J. Med. Chem. 142, 523\u2013549 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"52451_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242417190","volume":"24","author":"RE Trifonov","year":"2023","unstructured":"Trifonov, R. E. & Ostrovskii, V. A. Tetrazoles and related heterocycles as promising synthetic antidiabetic agents. Int. J. Mol. Sci. 24, 17190 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"52451_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0691-y","volume":"16","author":"KCG Berg","year":"2017","unstructured":"Berg, K. C. G. et al. Multi-omics of 34 colorectal cancer cell lines - A resource for biomedical studies. Mol. Cancer 16, 116 (2017).","journal-title":"Mol. Cancer"},{"key":"52451_CR65","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1038\/oncsis.2013.35","volume":"2","author":"D Ahmed","year":"2013","unstructured":"Ahmed, D. et al. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis 2, e71 (2013).","journal-title":"Oncogenesis"},{"key":"52451_CR66","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1158\/1535-7163.MCT-06-0166","volume":"5","author":"E Buck","year":"2006","unstructured":"Buck, E. et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol. Cancer Ther. 5, 2676\u20132684 (2006).","journal-title":"Mol. Cancer Ther."},{"key":"52451_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228010","volume":"15","author":"J Hofmanov\u00e1","year":"2020","unstructured":"Hofmanov\u00e1, J. et al. Phospholipid profiling enables to discriminate tumor- and non-tumor-derived human colon epithelial cells: Phospholipidome similarities and differences in colon cancer cell lines and in patient-derived cell samples. PLoS One 15, e0228010 (2020).","journal-title":"PLoS One"},{"key":"52451_CR68","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/978-1-0716-2736-5_16","volume":"2579","author":"J Yu","year":"2022","unstructured":"Yu, J., Wang, Z. & Wang, Y. BrdU incorporation assay to analyze the entry into S Phase. Methods Mol. Biol. Clifton NJ 2579, 209\u2013226 (2022).","journal-title":"Methods Mol. Biol. Clifton NJ"},{"key":"52451_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/0471142956.cy0731s40","author":"K Rothaeusler","year":"2007","unstructured":"Rothaeusler, K. & Baumgarth, N. Assessment of cell proliferation by 5-bromodeoxyuridine (BrdU) labeling for multicolor flow cytometry. Curr. Protoc. Cytom. https:\/\/doi.org\/10.1002\/0471142956.cy0731s40 (2007).","journal-title":"Curr. Protoc. Cytom."},{"issue":"Suppl","key":"52451_CR70","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.semcancer.2015.02.006","volume":"35","author":"MA Feitelson","year":"2015","unstructured":"Feitelson, M. A. et al. Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin. Cancer Biol. 35(Suppl), S25\u2013S54 (2015).","journal-title":"Semin. Cancer Biol."},{"key":"52451_CR71","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3390\/cells12040659","volume":"12","author":"M Kciuk","year":"2023","unstructured":"Kciuk, M. et al. Doxorubicin\u2014An agent with multiple mechanisms of anticancer activity. Cells 12, 659 (2023).","journal-title":"Cells"},{"key":"52451_CR72","volume":"1878","author":"A Gieleci\u0144ska","year":"2023","unstructured":"Gieleci\u0144ska, A. et al. Apoptosis, necroptosis, and pyroptosis as alternative cell death pathways induced by chemotherapeutic agents?. Biochim. Biophys. Acta (BBA) 1878, 189024 (2023).","journal-title":"Biochim. Biophys. Acta (BBA)"},{"key":"52451_CR73","doi-asserted-by":"publisher","first-page":"188716","DOI":"10.1016\/j.bbcan.2022.188716","volume":"1877","author":"M Kciuk","year":"2022","unstructured":"Kciuk, M., Gieleci\u0144ska, A., Mujwar, S., Mojzych, M. & Kontek, R. Cyclin-dependent kinases in DNA damage response. Biochim. Biophys. Acta Rev. Cancer. 1877, 188716 (2022).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"52451_CR74","first-page":"771","volume":"92","author":"JYJ Wang","year":"2019","unstructured":"Wang, J. Y. J. Cell death response to DNA damage. Yale J. Biol. Med. 92, 771\u2013779 (2019).","journal-title":"Yale J. Biol. Med."},{"key":"52451_CR75","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0076-6879(08)01606-6","volume":"446","author":"D Plesca","year":"2008","unstructured":"Plesca, D., Mazumder, S. & Almasan, A. DNA damage response and apoptosis. Methods Enzymol. 446, 107\u2013122 (2008).","journal-title":"Methods Enzymol."},{"key":"52451_CR76","doi-asserted-by":"publisher","unstructured":"Szymanowska, A. et al. The activity of pyrazolo[4,3-e][1,2,4]triazine and pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine sulphonamide derivatives in monolayer and spheroid breast cancer cell cultures. J Enzyme Inhib. Med. Chem 39(1):2343352 (2024). https:\/\/doi.org\/10.1080\/14756366.2024.2343352.","DOI":"10.1080\/14756366.2024.2343352"},{"key":"52451_CR77","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/cancers16010122","volume":"16","author":"I Kwiatkowska","year":"2023","unstructured":"Kwiatkowska, I. et al. Assessment of an anticancer effect of the simultaneous administration of MM-129 and indoximod in the colorectal cancer model. Cancers 16, 122 (2023).","journal-title":"Cancers"},{"key":"52451_CR78","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.3390\/molecules26072045","volume":"26","author":"A Gornowicz","year":"2021","unstructured":"Gornowicz, A. et al. The anticancer action of a novel 1,2,4-triazine sulfonamide derivative in colon cancer cells. Molecules 26, 2045 (2021).","journal-title":"Molecules"},{"key":"52451_CR79","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/cbin.11137","volume":"43","author":"MS D\u2019Arcy","year":"2019","unstructured":"D\u2019Arcy, M. S. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell. Biol. Int. 43, 582\u2013592 (2019).","journal-title":"Cell. Biol. Int."},{"key":"52451_CR80","first-page":"165","volume":"21","author":"D Kanduc","year":"2002","unstructured":"Kanduc, D. et al. Cell death: apoptosis versus necrosis (review). Int. J. Oncol. 21, 165\u2013170 (2002).","journal-title":"Int. J. Oncol."},{"key":"52451_CR81","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0163-7258(97)00037-5","volume":"75","author":"M Raffray","year":"1997","unstructured":"Raffray, M. & Cohen, G. M. Apoptosis and necrosis in toxicology: a continuum or distinct modes of cell death? Pharmacol. Ther. 75, 153\u2013177 (1997).","journal-title":"Pharmacol. Ther."},{"key":"52451_CR82","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1354\/vp.40-5-481","volume":"40","author":"CJ Zeiss","year":"2003","unstructured":"Zeiss, C. J. The apoptosis-necrosis continuum: Insights from genetically altered mice. Vet. Pathol. 40, 481\u2013495 (2003).","journal-title":"Vet. Pathol."},{"key":"52451_CR83","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.3390\/cancers15184466","volume":"15","author":"A van Rijt","year":"2023","unstructured":"van Rijt, A., Stefanek, E. & Valente, K. Preclinical testing techniques: Paving the way for new oncology screening approaches. Cancers 15, 4466 (2023).","journal-title":"Cancers"},{"key":"52451_CR84","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bcp.2013.06.020","volume":"87","author":"BA Ruggeri","year":"2014","unstructured":"Ruggeri, B. A., Camp, F. & Miknyoczki, S. Animal models of disease: Pre-clinical animal models of cancer and their applications and utility in drug discovery. Biochem. Pharmacol. 87, 150\u2013161 (2014).","journal-title":"Biochem. Pharmacol."},{"key":"52451_CR85","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jconrel.2012.02.031","volume":"164","author":"H HogenEsch","year":"2012","unstructured":"HogenEsch, H. & Nikitin, A. Y. Challenges in pre-clinical testing of anti-cancer drugs in cell culture and in animal models. J. Control. Release 164, 183\u2013186 (2012).","journal-title":"J. Control. Release"},{"key":"52451_CR86","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.3390\/cells14191498","volume":"14","author":"H Klepacki","year":"2025","unstructured":"Klepacki, H. et al. MM-129 counteracts 5-Fluorouracil-induced cellular senescence in colon cancer via SIRT1\/STAT3 signaling pathway. Cells 14, 1498 (2025).","journal-title":"Cells"},{"key":"52451_CR87","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2024.2343352","volume":"39","author":"A Szymanowska","year":"2024","unstructured":"Szymanowska, A. et al. The activity of pyrazolo[4,3-e][1,2,4]triazine and pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine sulphonamide derivatives in monolayer and spheroid breast cancer cell cultures. J. Enzyme Inhib. Med. Chem. 39, 2343352 (2024).","journal-title":"J. Enzyme Inhib. Med. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52451-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52451-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52451-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T13:02:40Z","timestamp":1786453360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52451-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["52451"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-52451-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,31]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24889"}}